Skip to main content Accessibility help

From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

  • Prakash S. Masand, Charles B. Nemeroff, John W. Newcomer, Jeffrey A. Lieberman, Alan F. Schatzberg, Peter J. Weiden, Clinton D. Kilts, Philip D. Harvey and David G. Daniel...


Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. It has a unique receptor profile that includes high-affinity antagonist activity at dopamine D2 receptors, inverse agonist activity at serotonin (5-HT)2A receptors, agonist activity at 5-HT1A receptors, and a relatively high affinity for the serotonin and norepinephrine transporters. The 5-HT1A affinity, together with the inhibitory effect on monoamine reuptake, may underlie the hypothesized beneficial effects on comorbid affective and cognitive abnormalities in schizophrenia and schizoaffective disorder. The short-term efficacy of ziprasidone for core positive symptoms of schizophrenia appears to be comparable to other conventional and atypical antipsychotics. The short-term efficacy of ziprasidone in acute mania has been established based on two 3-week, double-blind, placebo-controlled trials. Open-label treatment for up to 52 weeks confirms the sustained efficacy and safety of ziprasidone in bipolar disorder. Maintenance studies in schizophrenia and schizoaffective disorder indicate that long-term ziprasidone therapy is effective in preventing relapse, while maintaining cognitive and psychosocial benefits. The safety database suggests that the overall cardiovascular and cerebrovascular risk associated with ziprasidone is lower than with other atypicals, with notably lower risk of drug-related increases in weight, glucose, or lipids. The data also suggest a modestly increased risk of QTc prolongation that is not dose related or linked to torsades de pointes. Switching to ziprasidone from other atypicals appears to improve both clinical symptoms and metabolic parameters, though more studies are needed to fully characterize these benefits. This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania.



Hide All
1.Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, ER. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Beri). 2001;155:128134.
2.Lesem, MD, Zajecka, JM, Swift, RH, Reeves, KR, Harrigan, ER. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry. 2001;62:1218.
3.Brook, S, Walden, J, Benattia, I, Siu, CO, Romano, SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Beri). 2005;178:514523.
4.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:2939.
5.Shapiro, DA, Renock, S, Arrington, E, et al. Aripiprazole, a novel atypical anti-psychotic drug with a unique and robust pharmacology. Neuropsycbopharmacol. 2003;28:14001411.
6.Weiner, DM, Meitzer, HY, Veinbergs, I, et al. The role of Ml muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacol. 2004;177:207216.
7.Schmidt, AW, Lebel, LA, Howard, HR Jr, Zorn, SH. Ziprasidone: a novel anti-psychotic agent with a unique human receptor binding profile. Eur J Pharmacol. 2001;425:197201.
8.DeLeon, A, Patel, NC, Crismon, ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649666.
9.Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):612.
10.Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsycbopharmacol. 2003;28:519526.
11.Duman, RS. Depression: a case of neuronal life and death? Biol Psychiatry. 2004;56:140145.
12.Thome, J, Foley, P, Riederer, P. Neurotrophic factors and the maldevelopmen-tal hypothesis of schizophrenic psychoses. Review article. J Neural Tramm. 1998;105:85100.
13.Arango, C, Kirkpatrick, B, Koenig, J. At issue: stress, hippocampal neuronal turnover, and neuropsychiatrie disorders. Schizophr Bull. 2001;27:477480.
14.Garver, DL, Holcomb, JA, Christensen, JD. Cerebral cortical gray expansion assoeiated with two second-generation antipsychotics. Biol Psychiatry. 2005;58:6266.
15.Prakash, C, Kamel, A, Cui, D, Whalen, RD, Miceli, JJ, Tweedie, D. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol. 2000;49(suppl 1):35S42S.
16.Beedham, C, Miceli, JJ, Obach, RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229232.
17.Miceli, JJ, Wilner, KD, Hansen, RA. Single and multiple dose pharmacokinetics of ziprasidone under non-fasting conditions in healthymale volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S13S.
18.Hamelin, BA, Allard, S, Laplante, L, et al. The effect of timing of a standard meal on rhe pharmacokinetics and pharmacodynamics of the novel atypical antipsy-chotic agent ziprasidone. Pharmacotherapy. 1998;18:915.
19.Miceli, JJ, Smith, M, Robarge, L, Morse, T, Laurent, A. The effects of ketoconazole on ziprasidone pharmacokinetics: a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):S71S76.
20.Miceli, JJ, Anziano, RJ, Robarge, L, Hansen, RA, Laurent, A. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol. 2000; 49:(suppl 1):S65S70.
21.Apseloff, G, Mullet, D, Wilner, KD, et al. The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium. Br J Clin Pharmacol. 2000;49(suppl 1):S61S64.
22.Obach, RS, Huynh, P, Allen, MC, Beedham, C. Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol. 2004;44:719.
23. Geodon (package insert), New York, NY: Pfizer, Inc.; December 2003.
24.Murray, S, Mandel, FS, Loebel, A. Optimal initial dosing of ziprasidone: clinical trial data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
25.Mamo, D, Kapur, S, Shammi, CM, et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818825.
26.Weiden, PJ, Iqbal, N, Mendelowitz, AJ, Tandon, R, Zimbroff, DL, Ross, R. Best clinical practice with ziprasidone: Update after one year of experience. J Psych Pract. 2002;8:8197.
27.Joyce, AT, Harrison, DJ, Ollendorf, DA. Effect of ziprasidone initial dosing on discontinuation. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
28.Pozzi, L, Acconcia, S, Ceglia, I, et al. Stimulation of 5-hydroxytryptamine (5-HT(2Q) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex. J Neurochem. 2002;82:93100.
29.Bonaccorso, S, Meitzer, HY, Li, Z, et al. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsycbopharmacol. 2002;27:430441.
30.Harrigan, EP, Miceli, JJ, Anziano, R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:6269.
31.Daniel, DG. Tolerability of ziprasidone: an expanding perspective. J Clin Psychiatry. 2003;64(suppl 19):4049.
32.Deutschman, DA, Deutschman, DH. High-dose ziprasidone: Efficacy and toler-ability in clinical practice. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
33.Miceli, JJ, Murray, S, Sallee, FR, Tensfeldt, TG, Versavel, M. Phamacokinetic and pharmacodynamic QTc profile of oral ziprasidone in pediatric and adult subjects following single-dose administration. Poster presenred at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
34.Lindenmayer, JP, Czobor, P, Volavka, J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry. 2004;65:551556.
35.Lindenmayer, JP, Bernstein-Hyman, R, Grochowski, S, Bark, N. Psychopathology ot schizophrenia: initial validation of a 5-factor model. Psycbopatbology. 1990;28;2231.
36.Potkin, SG, Anand, R, Alphs, L, Fleming, K. Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk fur suicide. Schizophr Res. 2003;59:5966.
37.Heydebrand, G, Weiser, M, Rabinowitz, J, Hoff, AL, DeLisi, LE, Csernansky, JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:19.
38.Goff, DC, Posever, T, Herz, L, et al. An exploratory haloperidol-conrrolled dosefinding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296304.
39.Addington, D, Pantelis, C, Dineen, M. Ziprasidone vs risperidone in schizophrenia: 52 weeks' comparative data. Poster presented at: the 156th Annual Meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, CA.
40.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability ot ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:18371847.
41.Geddes, J, Freemantle, N, Hatrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J. 2000;321:13711376.
42.Bagnali, AM, Joncs, L, Ginnclly, L, et al. A systematic review of atypical antipsy-chotic drugs in schizophrenia. Health Tech Assess. 2003;7(13):1193.
43.Lieberman, JA, Stroup, TS, McEvoy, JP. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:12091223.
44.Harrison, DJ, Joyce, AT, Olldendorf, DA. Impact of atypical agents on outcomes of care in schizophrenia. Poster presented at: 158th Annual Meeting of the American Psychiatric Association; May 21-26, 2005; Atlanta, GA.
45.Siris, SG. Depression in schizophrenia: perspective in the era of “Atypical” antipsychotic agents. Am J Psychiatry. 2000;157:13791389.
46.Keck, PE Jr, Reeves, KR, Harrigan, EP, et al. Ziprasidone in the short-term treat-mem of patients with schizoaffective disorder: results from two double-blind, placebo-controlled, multicenter studies. J Clin Psychopharmacol. 2001;21:2735.
47.Daniel, DG, Zimbroff, DL, Potkin, SG, Reeves, KR, Harrigan, EP, Lakshminarayanan, M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsycbopharmacol. 1999;20:491505.
48.Keck, P Jr, Butfenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Beri). 1998;140:173184.
49.Kane, JM. Oral ziprasidone in the treatment of schizophrenia: a review of shortterm trials. J Clin Psychiatry. 2003;64(suppl 19):1925.
50.Elvevag, B, Goldberg, TE. Cognitive impairmenr in schizophrenia is the core of the disorder. Crtt Rev Neurobiol. 2000;14:121.
51.Gleen, MF, Nuechterlein, KH, Gold, JM, et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the N1MH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56:301307.
52.Davalos, DB, Compagnon, N, Heinlein, S, Ross, RG. Neuropsychological deficits in children associated with increased familial risk for schizophrenia. Schizophr Res. 2004;67:123130.
53.Palmer, BW, Heaton, RK, Paulsen, JS, et al. Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology. 1997;11:437446.
54.Harvey, PD, Keefe, RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry. 2001;158:176184.
55.Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426445.
56.Harvey, PD, Meitzer, H, Simpson, GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101113.
57.Harvey, PD, Siu, CO, Romano, S. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapili: in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacol 2004;172:324332.
58.Harvey, PD, Bowie, CR, Loebel, A. Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a 6-month, randomized, double-blind comparison of ziprasidone vs. olanzapine. J Neuropsych Clin Neurosci. In press.
59.Hegarty, JD, Baldessarini, RJ, Tohen, M. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994;151:14091416.
60.Dickerson, FB, Ringel, N, Parents, F. Predictors of residential independence among outpatients with schizophrenia. Psychiatr Serv. 1999;5:515519.
61.Macdonald, EM, Hayes, RL, Baglioni, AJ Jr. The quantity and quality of the social networks of young people with early psychosis compared with closely matched controls. Schizophr Res. 2000;46:2530.
62.Haukka, J, Suvisaari, J, Lonnqvist, J. Fertility of patients with schizophrenia, their siblings, and the general population: a cohort study from 1950 to 1959 in Finland. Am J Psychiatry. 2003;160:460463.
63.Purnine, DM, Carey, KB, Maistro, SM, Karey, MP. Assessing positive and negative symptoms in patients with schizophrenia and mood disorders. J Nerv Ment Dis. 2000;188:653661.
64.Loebel, A, Siu, C, Romano, S. Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr. 2004;9:357364.
65. The World Health Report: 2001. Mental Health: New Understanding, New Hope. Available at: hrtp://\2001/en/. Accessed October 4, 2005
66.Arato, M, O'Connor, R, Meitzer, HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207215.
67.Schooler, NR. Maintaining symptom control: review of ziprasidone longterm efficacy data. J Clin Psychiatry. 2003;64(suppl 19):2632.
68.Simpson, GM, Weiden, PJ, Loebel, A, Warrington, L, Yang, R. Ziprasidone: long-term post-switch efficacy in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
69.O'Connor, R, Schooler, NR. Penulrimate observation carried forward (POCF): a new approach to analysis of long-term symptom change in chronic relapsing conditions [letter]. Schizophr Res. 2003;60:319320.
70.Weiden, PJ, Simpson, GM, Potkin, SG, O'Sullivan, RL. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry. 2003;64:580588.
71.Weiden, PJ, Daniel, DG, Simpson, GM, Romano, SJ. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:16.
72.Contey, RR, Buchanan, RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull. 1997;23:663674.
73.Basu, A. Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues. Schizophr Res. 2004;71:445462.
74.Essock, SM, Hargreaves, WA, Covell, NH. Clozapine's effectiveness for patients in state hospitals: results from a randomized trial. Psychopharm Bull. 1996;32:683697.
75.Rosenheck, R, Cramer, J, Xu, W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med. 1997;337:809815.
76.Tuunainen, A, Wahlbeck, K, Gilbody, S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res. 2002;56:110.
77.Moncrieff, J. Clozapine, v. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry. 2003;183:161166.
78.Kane, J, Khanna, S, Giller, E, Rajadhyaksha, S, Loebel, A, Siu, E. Efficacy and tolerability of ziprasidone in treatment-resistant schizophrenia. Int Clin Psychopharmacol. In press.
79.Rothschild, AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996;19:237252.
80.Kessler, RC, McGonagle, KA, Zhao, S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comotbidity Survey. Arch Gen Psychiatry. 1994;51:819.
81.Rush, AJ, Thase, ME, Dube, S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003;53:743753.
82.Kohler, CG, Lallart, EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep. 2002;4:273278.
83.Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:12181226.
84.Tohen, M, Zhang, F, Keck, PE, et al. Olanzapine versus haloperidol in schizoaf-fective disorder, bipolar type. J Affect Disord. 2001;67:133140.
85.Tohen, M, Jacobs, TG, Grundy, SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2000;57:841849.
86.Tohen, M, Chengappa, KN, Suppes, T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:6269.
87.DelBello, MP, Schwiers, ML, Rosenberg, HL, Strakowski, SM. A double-blind, randomized, placebo-conrrolled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:12161223.
88.Casey, DE, Daniel, DG, Wassef, AA, Tracy, KA, Wozniak, P, Sommerville, KW. Effect of divalproex combined with olanzapine ot risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003;28:182192.
89.Brambilla, P, Barale, F, Soares, JC. Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacol. 2003;166:315332.
90.Hirschfeld, RM, Keck, PE Jr, Kramer, M, et al. Rapid anrimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:10571065.
91.Potkin, SG, Keck, P, Giller, E, Ice, K, Warrington, L, Mandel, FS. Ziprasidone in bipolar mania: efficacy across patient subgroups. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
92.Keck, PE, Potkin, S, Watrington, L, Loebel, A, Giller, E, Batzar, E. Efficacy and safety of ziprasidone in bipolar disorder: short- and long-term data. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.
93.Papakostas, Gl, Petersen, TJ, Neirenberg, AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSR I-res istant major depressive disorder. J Clin Psychiatry. 2004;65:217221.
94.Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001;179:498502.
95.Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:1153.
96.Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparen, P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844850.
97.Jamison, KR. Suicide and bipolar disorder. J Clin Psychiatry. 2000;61(suppl 9):4751.
98.Davidson, S, Judd, F, Jolley, D, Hocking, B, Thompson, S, Hyland, B. Cardiovascular risk factors for people with mental illness. Aust N Z J Psychiatry. 2001;35:196202.
99.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-induced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):418.
100.Zhang, ZJ, Yao, KJ, Liu, W, et al. Effects of anripsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry. 2004;184:5862.
101.Newcomer, J. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1): 193.
102.American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596601.
103.Simpson, GM, Glick, ID, Weiden, PJ, Romano, SJ, Siu, CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:18371847.
104.Simpson, GM, Weiden, P, Pigott, T, Murray, S, Siu, CO, Romano, SJ. Six-month, blinded, multicenter conrinuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry. 2005;162:15351538.
105.Sorensen, SV, Leaderer, MC, Harrison, DJ, et al. Psychiatric and metabolic outcomes of antipsychotics in schizophrenia. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2005; New Yotk, NY.
106.Marder, SR, McQuade, RD, Stock, E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61:123136.
107.Cheet, SM, Wagstaff, AJ. Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs. 2004; 18(3): 173199.
108.Fitzsimons, J, Berk, M, Lambert, T, Bourin, M, Dodd, S. A review of clozapine safety. Expert Opin Drug Saf. 2005;4(4):731744.
109.Pajonk, FG. Risperidone in acute and long-term rherapy of schizophrenia--a clinical profile. Prog Neuropsycbopharmacol Biol Psychiatry. 2004;28(1):1523.
110.Bhana, N, Foster, RH, Olney, R, Plosker, GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111161.
111.Moller, HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6(5):803818.
112.Swatnston Harrison, T, Perry, CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):17151736.
113. Clozaril (package insert). East Hanover, NJ: Novartis; January 2003.
114. Zyprexa (package insert). Indianapolis, IN: Eli Lilly; March 2004.
115. Abilify (package insert). Orsuka Pharmaceutical Co, Ltd (Tokyo) and Bristol-Myers Squibb (Princeton, NJ); March 2004.
116. Risperdal (package insert). Titusville, NJ: Janssen Pharmaceutical December 2003.
117. Seroquel (package insert). Wilmington, DE: AstraZeneca; January 2004.
118.Taylor, D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs. 2003;17:423430.
119.Montanez, A, Ruskin, JN, Hebert, PR, Lamas, GA, Hennekens, CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population. Arch Int Med. 2004;164:943948.
120.Goldberg, RJ, Bengtson, J, Chen, ZY, Anderson, KM, Locati, E, Levy, D. Duration of the QT interval and total and cardiovascular mortality in healthy persons (The Framingham Heart Study experience). Am J Cardiol. 1991;67:5558.
121.Casey, DE, Haupt, DW, Newcomer, JW, et al. Antipsychotic-tnduced weight gain and metabolic abnormalities: Implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65(suppl 7):418.
122.Allison, DB, Mentore, JL, Heo, M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:16861696.
123.Beasley, CM, Tollefson, GD, Tran, PV. Safety of olanzapine. J Clin Psychiatry. 1997;58:1317.
124.Meyer, JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425433.
125.Wilson, PW, D'Agostino, RB, Levy, D, Belanget, AM, Silbershatz, H, Kannel, WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:18371847.
126.Wolf, PA, Abbott, RD, Kannet, WB. Atrial fibrillation as an independent risk factor for srroke: the Framingham Study. Stroke. 1991;22:983988.
127.Harrison, DJ, Leaderer, MC, Loebel, A, Murray, S. Ziprasidone, vs. olanzapine: change in CHD risk during a 6 week trial. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; Atlanta, GA.
128.Newcomet, J, Lebovitz, H. Course of weight and metabolic benefits one-year after switching to ziprasidone. Posrer presented at: 157th Annual Meeting of the American Psychiarric Associarion; May 1-6, 2004; Atlanta, GA.
129.Street, JS, Clark, WS, Gannon, KS, et al. Olanzapine tteatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968976.
130.De Deyn, PP, Carrasco, MM, Deberdt, W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patienrs wirh Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115126.
131.Wooltorton, E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ. 2002;167:12691270.
132. FDA Warning about Hyperglycemia and Atypical Anripsychotic Drugs, June 2004. Availableat: cfm?id=229. Accessed October 4, 2005.
133.Weiden, Pj, Mackell, J, Macdonell, D. Obesity as a risk factor for noncompliance. Schizophrenia Res. 2004;66:5157.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed